

Curriculum Vitae

Personal information **Nectaroula Cooper**

Work experience

1. Employer: Pharmaceutical Services, Ministry of Health
 - Start date: 122021
 - End date:
 - Position: Head of GVP and GCP Inspections
 - Activities:
 - Country: Cyprus
2. Employer: Pharmaceutical Services, Ministry of Health
 - Start date: 032018
 - End date:
 - Position: Pharmacist / Inspector
 - Activities:
 - Administration
 - Regulatory Affairs
 - GMDP Inspectorate

Cyprus Member of the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency

Member of the national sub_committee of the Drugs Council for Pharmacovigilance

Member of the national sub_committee of the Drugs Council for Clinical Trials

Member of the national sub_committee of the Drugs Council for the legal classification of medicines

- Country: Cyprus
3. Employer: Nicosia General Hospital Pharmacy, Pharmaceutical Services, Ministry of Health
 - Start date: 012017
 - End date: 032018
 - Position: Pharmacist
 - Activities:
 - Country: Cyprus
 4. Employer: Pharmaceutical Services, Ministry of Health
 - Start date: 122013
 - End date: 122016
 - Position: Head of Pharmacovigilance
 - Activities:

EU contact point for Pharmacovigilance matters

PRAC (Pharmacovigilance Risk Assessment Committee) Member for Cyprus

Member of the national sub_committee on Pharmacovigilance

Member of the Strategic Planning Task Force

Product Shortages and development of policies concerning Medicines Accessibility

- Country: Cyprus
5. Employer: Pharmaceutical Services, Ministry of Health
 - Start date: 042011
 - End date: 122013
 - Position: Pharmacist
 - Activities:

Hospital pharmacist based at Nicosia General Hospital (from July 2011) with secondments to Limassol Outpatient Hospital (inc. rural pharmacy services in Limassol district). Pharmacist at Larnaca General Hospital (April 2011) and Responsible Pharmacist at Pyrgo Tyllirias Rural Health Centre (May – July 2011).

Member of the committee for infectious diseases at NGH.

- Country: Cyprus
6. Employer: Pavlidou & Michael Pharmacy
 - Start date: 042010
 - End date: 042011
 - Position: Locum Pharmacist
 - Activities: Part time locum Pharmacist
 - Country: Cyprus
 7. Employer: Medochemie Ltd.
 - Start date: 052007
 - End date: 032010
 - Position: Global QPPV and Regulatory Affairs officer
 - Activities:

•

Global and EU Qualified Person for Pharmacovigilance (EU_QPPV)

Product Quality Expert

RA country manager for Malta

API manufacturers qualification

- Country: Cyprus
- 8. Employer: Community Pharmacies, Limassol
 - Start date: 042004
 - End date: 042007
 - Position: Locum Pharmacist
 - Activities: Part time locum pharmacist.
 - Country: Cyprus
- 9. Employer: Community Pharmacies, London & Nottingham
 - Start date: 102000
 - End date: 092003
 - Position: Locum Pharmacist
 - Activities: Weekend Locum Pharmacist
 - Country: Cyprus
- 10. Employer: St George's Hospital, London
 - Start date: 022000
 - End date: 092000
 - Position: Pre_registration Pharmacist
 - Activities: Approved pre_registration practical training in hospital pharmacy.
 - Country: United Kingdom
- 11. Employer: Abbott Labs, Queenborough, Kent
 - Start date: 081999
 - End date: 012000
 - Position: Pre_registration Pharmacist
 - Activities: Approved pre_registration practical training in industrial pharmacy.
 - Country: United Kingdom
- 12. Employer: Remedica Pharmaceuticals Ltd., Limassol
 - Start date: 071998
 - End date: 091998
 - Position: Internship
 - Activities: Work experience in pharmaceutical Research and Development.
 - Country: Cyprus
- 13. Employer: Smith and Nephew Medical Ltd., Hull
 - Start date: 041998
 - End date: 051998
 - Position: Internship
 - Activities: Work experience in International Marketing.
 - Country: United Kingdom

Education and training

1. Subject: School of Pharmacy, University of London
 - Start date:
 - End date:
 - Qualification: PhD
 - Organisation:
 - Country: United Kingdom
2. Subject: University of Cyprus
 - Start date:
 - End date:
 - Qualification: Master in Business Administration (MBA)
 - Organisation:
 - Country: Cyprus
3. Subject: Member of the Royal Pharmaceutical Society
 - Start date:
 - End date:
 - Qualification: MRPharmS
 - Organisation:
 - Country: United Kingdom
4. Subject: University of Sunderland
 - Start date:
 - End date:
 - Qualification: BSc (Hons.) Pharmacy
 - Organisation:
 - Country: United Kingdom

Additional information

Publications

- Antonow, D.; Kaliszczak, M.; Kang, G. D.; Coffils, M.; Tiberghien, A. C.; Cooper, N.; Barata, T.; Heidelberger, S.; James, C. H.; Zloh, M.; Jenkins, T. C.; Reszka, A. P.; Neidle, S.; Guichard, S. M.; Jodrell, D. I.; Hartley, J. A.; Howard, P. W.; Thurston, D. E., Structure-activity relationships of monomeric C2_aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents. J Med Chem 2010, 53 (7), 2927_41.
- Howard, P. W.; Chen, Z.; Gregson, S. J.; Masterson, L. A.; Tiberghien, A. C.; Cooper, N.; Fang, M.; Coffils, M. J.; Klee, S.; Hartley, J. A.; Thurston, D. E., Synthesis of a novel C2/C2'-arylsubstituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. Bioorg Med Chem Lett 2009, 19 (22), 6463_6.
- Antonow, D.; Cooper, N.; Howard, P. W.; Thurston, D. E., Parallel synthesis of a novel C2_aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) library. J Comb Chem 2007, 9 (3), 437_45.
- Cooper, N.; Hagan, D. R.; Tiberghien, A.; Ademefun, T.; Matthews, C. S.; Howard, P. W.; Thurston, D. E., Synthesis of novel C2_aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. Chem Commun (Camb) 2002, (16), 1764_5.
- Cooper N, Hagan DR, Tiberghien A, Ademefun T, Matthews CS, Howard PW, et al. Synthesis of novel C2_aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. Chemical Biology Virtual Journal [serial online]. 2002;(14) [cited 2006 November 1]. Available from: URL: www.rsc.org/Publishing/Journals/cb/Index.asp.

Conference proceedings:

- Polypharmacy – Patient Safety and Quality of Life. Polythematic scientific conference 2012; 8 December 2012; Nicosia General Hospital.
- Howard PW, Antonow D, Cooper N, Stephenson M, Hartley JA, Jenkins TC, et al. Design, synthesis and biological evaluation of novel C2_aryl_substituted pyrrolo[2,1_c][1,4]benzodiazepine monomers. In: 97th AACR Annual Meeting; AACR Meeting Abstracts; 2006 April 1_5; Washington, DC. Philadelphia: Proc Amer Assoc Cancer Res (American Association for Cancer Research, Inc. (AACR)); 2006;47(1): p. 132_a_.
- Cooper N, Howard PW, Neidle S, Thurston DE. Synthesis and evaluation of novel C2_aryl pyrrolobenzodiazepine (PBD) monomers as potential clinical candidates. In: Mini E, Mazzei T, Novelli A, Nobili S, Forrest M, Landini I, et al., editors. 24th Winter Meeting of the EORTC PAMM Group; Journal of Chemotherapy Supplement (Abstracts); 2003 February 5_8; Convitto della Calza, Florence, Italy. Firenze: J. Chemother. (University of Florence); 2003;15(Supplement 1): p. 129 (P22).
- Cooper N, Burger AM, Fiebig HH, Howard PW, Neidle S, Thurston DE. Structure_Activity_Relationship (SAR) study of novel C2/C3_ unsaturated C2_aryl_substituted pyrrolobenzodiazepine monomer antitumour agents. In: Smyth JF, editor. 14th EORTC_NCIAACR symposium on Molecular Targets and Cancer Therapeutics; European Journal of Cancer; 2002 November 19_22 Frankfurt am Main, Germany. Oxford: Eur. J. Cancer (Pergamon/Elsevier); 2002;38(Supplement 7): p. S122.
- Cooper N, Hagan DR, Ademefun T, Tiberghien A, Matthews CS, Burger AM, et al. Synthetic C2_aryl pyrrolobenzodiazepines as potential melanoma chemotherapy agents. In: Lejeune FJ, Riley PA, Storkus WJ, editors. 4th International Conference on the Adjuvant Therapy of Malignant Melanoma; 2002 March 15_16; Royal College of Physicians, London, UK. London: Melanoma Res. (Lippincott Williams & Wilkins); 2002;12(3): p. A24_A40.
- Cooper N, Hagan DR, Ademefun T, Tiberghien A, Gregson SJ, Howard PW, et al. Design, synthesis and evaluation of novel anti_melanoma agents. In: York P, editor. 138th British Pharmaceutical Conference; Science Proceedings 2001; 2001 September 23_26; Glasgow, Scotland. London: J. Pharm. Pharmacol. (Pharmaceutical Press); 2001; p. 243.
- Cooper N, Howard PW, Neidle S, Thurston DE. Synthesis and evaluation of novel C2_aryl pyrrolobenzodiazepine (PBD) monomers as potential clinical candidates. In: CRUK Students Meeting 2003; 2003 19 May 2003; London, UK.
- Cooper N, Burger AM, Matthews CS, Howard PW, Thurston DE. Synthetic C2_aryl pyrrolobenzodiazepines as potential melanoma chemotherapy agents. In: Zloh M, chair. School of Pharmacy Postgraduate Research Day; 2002 April 17; School of Pharmacy, University of London, London, UK.
- Cooper N. Audit on the Frequency of Blood_Glucose Testing in St. George's Hospital In_Patients. In: Pharmacy Pre_Registration Meeting _ South Thames Region; 2000 July 13; Guys & Thomas' Hospital, London, UK

Projects

"Accessibility and Affordability of Innovative Medicines throughout the EU Market", Pharmaceutical Services, Ministry of Health, Cyprus, 2018 (ongoing)

"Legalisation of Medicinal Cannabis for Medical Use", Ministry of Health, Cyprus, 2016 _ 2018 (ongoing)

"Establishment of a National Medicines Agency in Cyprus", Ministry of Health, Cyprus, 2016 _ 2018 (ongoing)

"Polypharmacy _ detailed analysis of the problem in public health care", Pharmaceutical Services, Ministry of Health, Cyprus, 2018

"New Innovative Medicines Procurement in the Context of Small Markets", Pharmaceutical Services, Ministry of Health, Cyprus, 2015

"Pharmaceutical Services, State of Play, Objectives and Activities (ABB)", Ministry of Health, Cyprus, 2015

"Working Group for the Management of Cancer Medication" Cyprus Ministry of Health.

"Polypharmacy _ patient safety and quality of life", Nicosia General Hospital, 2012

"Hazardous drugs in the hospital setting", Nicosia General Hospital, 2012

"Audit on the frequency of blood glucose testing in St George's Hospital in_patients", London, 2000

"Synthesis of anthraquinone_amino acid conjugates as potential topoisomerase inhibitors in the treatment of cancer", Sunderland, 1999

Memberships

Registered Pharmacist with the General Pharmaceutical Council, Great Britain

Member of the Royal Pharmaceutical Society, GB

Registered Pharmacist of the Republic of Cyprus

Member of the Academy of Pharmaceutical Sciences, UK

Committees

- Member of the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) (Representing Cyprus)
- Member of the Clinical Trials Committee of the Drugs Council (Cyprus)
- Member of the Pharmacovigilance Committee of the Drugs Council (Cyprus)
- Member of the Legal Classification of Medicines Committee of the Drugs Council (Cyprus)

Formerly:

- PRAC (Pharmacovigilance Risk Assessment Committee at the European Medicines Agency) Member for Cyprus
- Pharmacovigilance Business Team (EMA) Member
- EU Network Training Center Learning Management System Local Administrator
- Member of the Infectious Diseases committee, Nicosia General Hospital, Cyprus
- Member of Task Force for the development and implementation of guidelines on the safe handling of hazardous drugs, Nicosia General Hospital
- Lead of 'Working Group for the Management of Cancer Medication', Ministry of Health, Cyprus

Other Relevant Information

Awards

The Schering-Plough Young Investigator Award, '4th International Conference on the Adjuvant Therapy of Malignant Melanoma', Royal College of Physicians, London March 2002.